What is the SARS‑CoV‑2 spike protein antibody and how is it measured to assess immunity after infection or vaccination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

SARS-CoV-2 Spike Protein Antibody

The SARS-CoV-2 spike protein antibody is an immunoglobulin (IgG, IgM, or IgA) produced by the immune system that specifically targets the spike (S) protein on the surface of the SARS-CoV-2 virus, and it is measured using serological immunoassays such as chemiluminescent immunoassays (CLIAs), enzyme-linked immunosorbent assays (ELISAs), or bead-based assays to assess immunity following infection or vaccination. 1

What is the Spike Protein Antibody?

The spike protein antibody represents the body's humoral immune response to the SARS-CoV-2 spike protein, which is the primary surface glycoprotein the virus uses to bind to human cells via the ACE2 receptor. 2, 3 The spike protein exists in a native trimeric form on the viral surface, and antibodies targeting this structure—particularly the receptor-binding domain (RBD)—can neutralize the virus by blocking its ability to enter host cells. 2, 4

Types of Antibodies Produced

Following SARS-CoV-2 infection or vaccination, the immune system generates several antibody classes:

  • IgM antibodies: Develop in most patients (>50%) and peak approximately 20 days after symptom onset or PCR diagnosis, remaining detectable for at least 115 days with moderate certainty. 1

  • IgG antibodies: Develop in nearly all patients (>90%) and peak approximately 25 days after symptom onset or PCR diagnosis, remaining detectable for at least 120 days with moderate certainty. 1

  • IgA antibodies: Develop in most patients and peak approximately 16-30 days after symptom onset, remaining detectable for at least 140 days with low certainty. 1

  • Neutralizing antibodies: Develop in nearly all patients (>90%) and peak approximately 31 days after symptom onset, remaining detectable for at least 152 days with low certainty. 1

How Spike Antibodies Are Measured

Immunoassay Platforms

Multiple validated platforms exist for measuring spike protein antibodies, each with distinct characteristics:

  • Chemiluminescent immunoassays (CLIAs): Automated platforms from Abbott, Roche, and Siemens detect >90% of samples collected 14 days after symptom onset, with detection rates ranging from 92.3% to 97.4%. 5 These assays show good correlation (r = 0.763-0.885) but are not directly interchangeable due to proportional differences between platforms. 5

  • Enzyme-linked immunosorbent assays (ELISAs): Can measure both antibody binding and functional blocking of the ACE2 receptor to the spike protein, providing information about antibody functionality. 2

  • Bead-based assays (Luminex xMAP): Offer quantitative measurement with a linear range typically between 300-5,000 mean fluorescence intensity (MFI) units. 6 Among fully vaccinated individuals, 84.8% have anti-RBD values above 5,000 MFI, with those having hybrid immunity (vaccination plus past infection) showing 97% with values >5,000 MFI. 6

  • Surface plasmon resonance (SPR): Can simultaneously quantitate antibody binding to spike protein and blocking of the ACE2 receptor in a single experiment. 2

  • Rapid point-of-care tests: The DPP SARS-CoV-2 IgM/IgG Assay differentially detects IgM and IgG antibodies to the RBD with diagnostic sensitivity of 83-100% (depending on infection stage) at 99-100% specificity. 7

Standardization Using WHO International Standards

Accurate quantification requires standardization using WHO binding antibody units (BAU)/mL. 6, 5 When samples are diluted within the linear range and quantified using WHO standards, BAU levels are significantly higher than semiquantitative MFI results, allowing for meaningful comparisons over time and between subjects. 6

Critical Technical Considerations

  • Antigen form matters significantly: Assays using the native trimeric spike protein are significantly more sensitive than those using monomeric S1 protein, as the trimer contains more conformational epitopes for antibody binding. 4

  • Target protein selection impacts results: Anti-spike antibody responses persist longer than anti-nucleocapsid (N) protein responses in the post-infection phase. 4 Using only N protein assays can underestimate seroprevalence by 9.4-31% in the general population and up to 45% in certain groups compared to spike protein assays. 4

  • Sample dilution is essential: With hybrid immunity now common, protocols must be adapted for high antibody levels to ensure measurements fall within the linear range of the assay. 6

Antibody Response Patterns

Post-Infection vs. Post-Vaccination

Vaccination induces higher circulating anti-spike IgG antibody levels and avidity compared to natural infection at similar time intervals. 8

  • mRNA-1273 (Moderna) produces significantly higher circulating antibody concentrations at 4 months post-vaccination compared to BNT162b2 (Pfizer), though both produce similar levels at 1 month. 8

  • mRNA-1273 induces significantly higher antibody avidity at month 1 compared to BNT162b2 across all age groups, with the 23-34 age group maintaining this difference through 4 months. 8

Factors Affecting Antibody Levels

  • Disease severity: More severe COVID-19 illness is associated with more robust antibody responses in terms of antibody levels (low certainty). 1

  • Symptom presence: Symptomatic infection is associated with higher antibody prevalence and levels compared to asymptomatic infection (low certainty). 1

  • Age: Older age may be associated with higher antibody levels (low certainty). 1

  • Sex: The antibody response to SARS-CoV-2 infection may not vary significantly by sex (low certainty), though male BNT162b2 recipients show trends toward lower anti-spike IgG avidity by month 4. 1, 8

Clinical Applications and Limitations

Appropriate Uses

Antibody tests can be useful for estimating community prevalence of SARS-CoV-2 infection. 1 Additional appropriate uses include:

  • Investigating patients presenting late after symptom onset when viral nucleic acid testing is negative. 9
  • Determining antibody presence as part of broader immunological assessment in vaccine efficacy studies. 9
  • Estimating seroprevalence of past and recent infection for public health decisions. 9
  • Monitoring immune response after vaccination using quantitative assays standardized to WHO BAU. 6, 5

Critical Limitations

Do not use SARS-CoV-2 antibody tests for the diagnosis of acute SARS-CoV-2 infection. 1 This is because:

  • Not all patients develop detectable antibodies early in infection. 1
  • Antibody presence and levels vary by patient and disease characteristics. 1
  • Tests may yield false-positive results due to cross-reactivity with antibodies to other coronaviruses. 1
  • SARS-CoV-2 serologic tests vary in accuracy, with insufficient evidence on associations between different tests and presence of detectable antibodies. 1

Correlation with Neutralization

CLIAs show good performance in predicting surrogate virus neutralization test (sVNT) positivity, with area under the curve values of 0.959-0.987. 5 The Abbott assay demonstrates the highest predictive value. 5 Functional assays measuring ACE2 receptor blocking correlate with pseudovirus neutralization titers. 2

Mucosal Antibody Detection

High correlation exists between circulating and mucosal antibody levels, as well as between binding IgG and neutralizing antibodies detected in blood, serum, nasal fluid, and oral fluid samples. 7 Rapid serologic tests used with nasal swab specimens offer a simple, non-invasive approach for monitoring post-vaccination humoral immunity. 7

References

3
Research

SARS-CoV-2 spike protein: structure, viral entry and variants.

Nature reviews. Microbiology, 2025

Related Questions

What is considered a normal SARS‑CoV‑2 spike protein antibody level?
Is a COVID-19 (Coronavirus Disease 2019) spike protein level of 96 considered high?
Are elevated SARS‑CoV‑2 spike protein antibody levels harmful?
What are the possible causes of leukopenia and thrombocytopenia, and can the SARS‑CoV‑2 spike protein induce them?
Is nicotinamide supplementation recommended for patients with a history of melanoma?
What does it mean when two consecutive blood pressure readings differ significantly?
How should I evaluate and manage a patient with mild hyponatremia (serum sodium 129 mmol/L) and mild‑to‑moderate hypokalemia (serum potassium 3.2 mmol/L)?
Are elevated SARS‑CoV‑2 spike protein antibody levels harmful?
What is the recommended duration of intravenous Piperacillin‑tazobactam therapy for a respiratory tract infection and the appropriate oral step‑down antibiotic regimen?
Is transdermal estradiol appropriate for a post‑menopausal woman needing hormone therapy for vasomotor symptoms, genitourinary atrophy, or osteoporosis prevention, particularly if she has venous thromboembolism risk factors or wishes to avoid first‑pass hepatic metabolism?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.